BR112013033472A2 - derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação - Google Patents
derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicaçãoInfo
- Publication number
- BR112013033472A2 BR112013033472A2 BR112013033472A BR112013033472A BR112013033472A2 BR 112013033472 A2 BR112013033472 A2 BR 112013033472A2 BR 112013033472 A BR112013033472 A BR 112013033472A BR 112013033472 A BR112013033472 A BR 112013033472A BR 112013033472 A2 BR112013033472 A2 BR 112013033472A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- application
- pharmaceutical composition
- camptothecin derivative
- camptothecin
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
- C07F9/65335—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101814060A CN102850400A (zh) | 2011-06-30 | 2011-06-30 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
| PCT/CN2012/000712 WO2013000269A1 (zh) | 2011-06-30 | 2012-05-22 | 喜树碱衍生物及其制备方法、药物组合物与用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013033472A2 true BR112013033472A2 (pt) | 2017-03-14 |
Family
ID=47397427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013033472A BR112013033472A2 (pt) | 2011-06-30 | 2012-06-25 | derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9266911B2 (pt) |
| EP (1) | EP2727927B1 (pt) |
| JP (1) | JP5819523B2 (pt) |
| KR (1) | KR101606624B1 (pt) |
| CN (2) | CN102850400A (pt) |
| AU (1) | AU2012276175B2 (pt) |
| BR (1) | BR112013033472A2 (pt) |
| CA (1) | CA2838875C (pt) |
| EA (1) | EA021814B1 (pt) |
| WO (1) | WO2013000269A1 (pt) |
| ZA (1) | ZA201309559B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015113176A1 (zh) | 2014-01-28 | 2015-08-06 | 周文强 | 喜树碱衍生物在制备用于治疗多发性骨髓瘤的药物中的用途 |
| CN118221763A (zh) * | 2019-03-29 | 2024-06-21 | 免疫医疗有限公司 | 化合物及其缀合物 |
| AU2020309244A1 (en) | 2019-07-11 | 2022-03-03 | Sun Pharma Advanced Research Company Ltd. | Camptothecin derivatives with a disulfide moiety and a piperazine moiety |
| CN114729035B (zh) * | 2019-12-16 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 抗cea抗体-依喜替康类似物偶联物及其医药用途 |
| AR125473A1 (es) | 2021-04-29 | 2023-07-19 | Abbvie Inc | Conjugados de anticuerpo anti-c-met y fármaco |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62195393A (ja) * | 1986-02-21 | 1987-08-28 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造方法 |
| JPS62195394A (ja) * | 1986-02-24 | 1987-08-28 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| WO2007095389A2 (en) * | 2006-02-17 | 2007-08-23 | Novacea, Inc. | Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs |
| US20080293648A1 (en) * | 2007-01-05 | 2008-11-27 | Saha Pharmaceuticals, Inc. | Compositions and Methods for Cancer Treatment |
| CN102153607B (zh) * | 2010-02-11 | 2015-07-15 | 湖南方盛华美医药科技有限公司 | 水溶性喜树碱衍生物及包含其的药物组合物 |
-
2011
- 2011-06-30 CN CN2011101814060A patent/CN102850400A/zh active Pending
-
2012
- 2012-05-22 WO PCT/CN2012/000712 patent/WO2013000269A1/zh active Application Filing
- 2012-05-22 EP EP12804633.1A patent/EP2727927B1/en active Active
- 2012-05-22 JP JP2014517395A patent/JP5819523B2/ja active Active
- 2012-05-22 EA EA201370251A patent/EA021814B1/ru not_active IP Right Cessation
- 2012-05-22 AU AU2012276175A patent/AU2012276175B2/en active Active
- 2012-05-22 CA CA2838875A patent/CA2838875C/en active Active
- 2012-05-22 CN CN201280032341.6A patent/CN103814036B/zh active Active
- 2012-05-22 KR KR1020137034087A patent/KR101606624B1/ko active IP Right Grant
- 2012-06-25 BR BR112013033472A patent/BR112013033472A2/pt not_active IP Right Cessation
-
2013
- 2013-12-18 ZA ZA2013/09559A patent/ZA201309559B/en unknown
- 2013-12-19 US US14/134,346 patent/US9266911B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2727927B1 (en) | 2016-07-20 |
| KR20140020333A (ko) | 2014-02-18 |
| EP2727927A4 (en) | 2015-02-11 |
| EP2727927A1 (en) | 2014-05-07 |
| EA201370251A1 (ru) | 2014-04-30 |
| WO2013000269A1 (zh) | 2013-01-03 |
| ZA201309559B (en) | 2014-08-27 |
| AU2012276175A1 (en) | 2014-01-09 |
| CN103814036A (zh) | 2014-05-21 |
| CA2838875A1 (en) | 2013-01-03 |
| CN102850400A (zh) | 2013-01-02 |
| EA021814B1 (ru) | 2015-09-30 |
| KR101606624B1 (ko) | 2016-03-25 |
| CA2838875C (en) | 2016-06-21 |
| US9266911B2 (en) | 2016-02-23 |
| US20140107342A1 (en) | 2014-04-17 |
| JP2014520762A (ja) | 2014-08-25 |
| AU2012276175B2 (en) | 2016-08-11 |
| CN103814036B (zh) | 2016-05-18 |
| JP5819523B2 (ja) | 2015-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6880066A2 (es) | Composición farmacéutica de sabor enmascarado | |
| BR112013030472A2 (pt) | formulação farmacêutica, artigo de fabricação e método | |
| HK1215028A1 (zh) | 驅蠕蟲化合物和組合物和使用其的方法 | |
| SMT201600194B (it) | Composizione e formulazione comprendente iduronato-2-s0lfatasi umano ricombinante e suo metodo di preparazione | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| FI20135146L (fi) | Farmaseuttiset koostumukset ja hoitomenetelmät | |
| BR112015002755A2 (pt) | derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados | |
| BR112014012005A2 (pt) | composições, métodos, formulação farmacêutica e artigo | |
| CO6970609A2 (es) | Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona | |
| BR112014001991A2 (pt) | certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| BR112012023355A2 (pt) | composto, composição farmacêutica e método de ruptura da interação nek2/hec1 | |
| ZA201403195B (en) | Pharmaceutical compositions of hydrophobic camptothecin derivatives | |
| PL2814463T3 (pl) | Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania | |
| HK1203815A1 (en) | Pharmaceutical compositions and methods for their preparation | |
| HRP20180567T1 (hr) | Farmaceutski pripravak omeprazola | |
| BR112014009822A2 (pt) | composições farmacêuticas compreendendo dgla e/ou 15-hetre e métodos de uso dos mesmos | |
| SMT201500005B (it) | Composizione framaceutica inalabile | |
| BR112014002804A2 (pt) | revestimento e método de preparação do mesmo | |
| IL231505A0 (en) | Pharmaceutical preparation and method for its production | |
| BR112013033472A2 (pt) | derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação | |
| HK1188791A1 (zh) | 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途 | |
| BR112013034066A2 (pt) | método de administração e tratamento | |
| SG11201401454XA (en) | Derivative of butylphthalide and preparation method and use thereof | |
| BR112013022530A2 (pt) | método terapêutico homeopático e composições |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |